Gustavo Alva

Detection of Amyloid β Signature in the Lens and Its Correlation in the Brain to Aid in the Diagnosis of Alzheimer's Disease.

We report the findings from a clinical trial in which a group of patients clinically diagnosed with probable Alzheimer’s disease (AD) were discriminated from an age-matched group of healthy volunteers (HVs) with statistical significance (P < .001). The results from 20 patients with AD and 20 HVs were obtained by a Fluorescent Ligand Eye Scanning (FLES) technique that measures a fluorescent signature specific to an exogenous ligand bound to amyloid-β in the lens of the eye. Sensitivity and specificity of 85% and 95%, respectively, have been achieved in predicting clinical diagnosis. Additionally, amyloid brain imaging using florbetapir F18 positron emission tomography shows significant correlation with the results obtained in the eye. Results of the study demonstrate the safety of the FLES system.

Efficacy of higher-dose 13.3 mg/24 h (15 cm2) rivastigmine patch on the Alzheimer's Disease Assessment Scale–cognitive subscale: domain and individual item analysis

Rivastigmine displays dose‐dependent efficacy on cognition in patients with Alzheimers disease (AD), as measured by the Alzheimers Disease Assessment Scale–cognitive subscale (ADAS‐cog). Subanalysis of the OPTIMA (OPtimising Transdermal Exelon In Mild‐to‐moderate Alzheimers disease) study aimed to define ADAS‐cog domains by factor analysis of individual items. Efficacy of 13.3 mg/24 h versus 9.5 mg/24 h rivastigmine patch on individual items and newly derived domains was assessed.